US Phase III clearance moves Green Cross' Factor VIII closer to global market
This article was originally published in Scrip
Green Cross is looking to broaden the geographical horizons for its recombinant coagulation Factor VIII product GreenGene F (beroctocog alfa), which it views as a key growth product over the mid-term period.
You may also be interested in...
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.